Brain Tumours
Conditions
Brief summary
The HuR protein binds to AU-rich elements in the untranslated 3' region of messenger RNA, thus allowing their stabilization. Its targets include multiple cell cycle regulating proteins, cytokines and growth factors. In some cancers, its overall expression level but especially its cytoplasmic expression are correlated to a higher grade and constitute a poor prognostic factor. To date, HuR's deregulation mechanisms remain poorly understood. A few experimental studies have shown the role of certain microARNS, or of post-translational modifications. In brain tumours, HuR expression, its prognostic value and its deregulation mechanisms have been little studied to date. The first part of the project will be a monocentric retrospective study of human brain tumour samples collected during biopsies or surgical removal. We will first evaluate HuR expression in 140 brain tumors, including 40 meningiomas and 100 gliomas of increasing grade, and look for a correlation with histological grade and survival. We will then apprehend the consequences of its deregulation by analyzing different factors involved in the cell cycle and stress response markers. Finally, we will study the mechanisms of HuR deregulation by analyzing the expression level of several microRNAs (miR16, miR519) and the methylation state of HuR. The second part of the project will focus on cell lines from human brain tumours. We will first attempt to confirm the interactions between HuR and markers involved in the cell cycle and stress response, then the regulation of HuR by its methylation and by microRNAs (miR16 and miR519). We would also like to study the consequences of HuR inhibition and overexpression on cell proliferation, under various conditions of induced stress (pharmacological agents, physical stress). Finally, we will study the consequences of an experimental vitamin B12 deficiency on HuR expression and tumor cell adaptation to stress.
Interventions
None listed
Sponsors
Central Hospital, Nancy, France
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Grade I and II meningiomas (WHO) * Diffuse grade II glioma (astrocytoma, oligodendroglioma) * Grade III anaplastic gliomas (astrocytomas and anaplastic oligodendrogliomas) * Grade IV glioblastoma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| time overall survival | through study completion, an average 3 years |
| time progression-free | through study completion, an average 3 years |
| level HuR's immunohistochemical expression | at diagnosis |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| MCM6 level | 1 day at diagnosis | — |
| Ki-67 level | 1 day at diagnosis | — |
| cyclin D1 level | 1 day at diagnosis | — |
| Bcl-2 | 1 day at diagnosis | — |
| pPERK level | 1 day at diagnosis | — |
| ATF6 level | 1 day at diagnosis | — |
| SIRT1 level | 1 day at diagnosis | — |
| IRE-1α level | 1 day at diagnosis | — |
| HIF-1α level | 1 day at diagnosis | — |
| caspase 3 activated level | 1 day at diagnosis | — |
| VEGF level | 1 day at diagnosis | — |
| CARM1 level | 1 day at diagnosis | Vitamin B12 metabolism |
| miR16 expression level by qRT-PCR | 1 day at diagnosis | — |
| miR519 expression level by qRT-PCR | 1 day at diagnosis | — |
| methyl-HuR level | 1 day at diagnosis | — |
| PHH3 level | 1 day at diagnosis | — |
Countries
France
Contacts
Primary ContactGuillaume GAUCHOTTE, PU-PH
Outcome results
None listed